Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib in Advanced NSCLC With Rare EGFR Mutations
NCT06029816Phase 2Not yet recruiting
- Sponsor
- Convalife Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of neratinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Convalife Pharmaceutical. Primary endpoint: Objective Response Rate at 1 year. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
neratinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06029816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029816.